Skip to main content
Professional Technical IVT

enoxaparin

Pronunciation: /ɪˈnɒksəpærɪn/

Low molecular weight heparin used for anticoagulation in pediatric patients with thrombotic complications or central line protection.

Full Definition

Enoxaparin is a low molecular weight heparin (LMWH) derived from unfractionated heparin through controlled depolymerization. In pediatric hematology, it is commonly used for treatment and prevention of venous thromboembolism, particularly in patients with central venous catheters or inherited thrombophilia. Enoxaparin has more predictable pharmacokinetics than unfractionated heparin and typically requires less frequent monitoring. Dosing in children is weight-based and often requires anti-factor Xa level monitoring to ensure therapeutic ranges.

Usage

Usage note: Generic name preferred over brand name Lovenox. Include dosing units when mentioned.

In Context

  • "The patient was started on enoxaparin 1 mg/kg subcutaneously twice daily for central line thrombosis." — Treatment plan
  • "Anti-factor Xa levels should be monitored 4 hours after the third dose of enoxaparin." — Clinical protocol

Also known as

Lovenox low molecular weight heparin LMWH

Contrasted with

unfractionated heparin

Don't confuse with

fondaparinux dalteparin heparin

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON